Fexofenadine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Fexofenadine: From Allergic Rhinitis to Rosacea Conjunctivitis
One-Sentence Summary
Fexofenadine is a second-generation H1-antihistamine, originally used for allergic rhinitis, allergic and other forms of conjunctivitis, and idiopathic urticaria. The TxGNN model predicts it may be effective for rosacea conjunctivitis, but no clinical trials and no publications currently support this direction, so it is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Allergic rhinitis, vasomotor rhinitis, atopic conjunctivitis, papillary conjunctivitis, vernal conjunctivitis, idiopathic urticaria (from the knowledge-graph indication edges; no approved indication text is available in the Singapore licence records) |
| Predicted New Indication | Rosacea conjunctivitis |
| TxGNN Prediction Score | 99.85% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 7 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on general knowledge, fexofenadine is a selective peripheral H1-receptor antagonist. It blocks histamine-mediated itching, redness and swelling, and it is already used for allergic and atopic conjunctivitis.
A histamine-driven component could plausibly contribute to ocular surface inflammation in rosacea, which is the basis for the prediction. However, rosacea conjunctivitis is mainly driven by meibomian gland dysfunction, microbial and Demodex factors, and innate immune and neurovascular dysregulation. H1 blockade does not address these causes.
The high score most likely reflects the closeness of rosacea conjunctivitis to other conjunctivitis indications in the knowledge graph. It is not supported by clinical data. At most, a symptomatic benefit (itch and redness) is conceivable.
Other Predicted Indications (all L5, Hold)
None of the following has trial or literature support.
| Rank | Predicted Indication | TxGNN Score | Assessment |
|---|---|---|---|
| 2 | Punctate epithelial keratoconjunctivitis | 98.63% | Usually infectious or dry-eye related; oral antihistamines may worsen dryness |
| 3 | Blepharoconjunctivitis | 98.40% | Plausible only for the allergic subtype |
| 4 | Viral conjunctivitis | 98.17% | No antiviral activity; symptom relief at most |
| 5 | Parasitic eyelid infestation | 96.67% | No antiparasitic action |
| 6 | Ulcerative blepharitis | 96.59% | Usually bacterial; adjunctive anti-itch effect only |
| 7 | Infective urethral stricture | 96.33% | No credible mechanistic link |
| 8 | Postinfectious vasculitis | 96.13% | Weak link; symptom control in urticarial vasculitis only |
| 9 | Post-bacterial disorder | 96.11% | Non-specific category; no defined hypothesis |
| 10 | Noninfectious dermatoses of eyelid | 95.84% | Most biologically plausible (histamine-mediated itch), but antihistamines have limited efficacy in eczema |
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN11704P | TELFAST TABLET 120 mg | Film-coated tablet | Not stated in the records |
| SIN11699P | TELFAST TABLET 180 mg | Film-coated tablet | Not stated in the records |
| SIN14591P | FEXODIN FILM COATED TABLET 180MG | Film-coated tablet | Not stated in the records |
| SIN15714P | FEXODIN FILM COATED TABLET 120MG | Film-coated tablet | Not stated in the records |
| SIN16296P | FEXOFEN FILM-COATED TABLET 180MG | Film-coated tablet | Not stated in the records |
Two further valid single-ingredient registrations exist: Telfast Oral Suspension 6 mg/ml (SIN14199P) and Telfast D Tablet (SIN12071P). All 7 registrations are valid and none are cancelled. Available forms are oral film-coated tablets and an oral suspension; no topical or ophthalmic formulation is registered.
Safety Considerations
- Disease-level cautions from the knowledge graph (not taken from label text): hypertension, kidney disease, diabetes mellitus and diabetic ketoacidosis, benign prostatic hyperplasia, coronary artery disease and atherosclerosis, angle-closure glaucoma, and hyperthyroidism (Graves disease, thyrotoxicosis). These should be verified against the approved package insert.
- Drug Interactions: 100 interactions were found in total. Examples from the records:
- Moderate: antacids containing aluminium or magnesium (aluminium hydroxide, magnesium hydroxide, magaldrate, magnesium carbonate), eliglustat, eluxadoline, rolapitant
- Minor: clarithromycin, miconazole, clotrimazole
- Severity not classified: cimetidine, famotidine, epinephrine, doxycycline, acetylsalicylic acid, among others
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on model score alone (L5). No trials or publications exist, and the underlying pathology of rosacea conjunctivitis is not histamine-driven. The oral formulations registered in Singapore also do not match the likely ocular-surface need.
To proceed, the following is needed:
- A focused literature review of antihistamines in rosacea-related ocular disease and, as a more plausible lead, eyelid dermatitis
- Detailed mechanism of action data
- Package insert warnings and contraindications from the HSA, to complete safety screening
- Assessment of route compatibility (oral versus topical ocular delivery)
- Specific indication text for the Singapore registrations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.